Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical, granting the latter exclusive rights to commercialise Sol-Gel’s dermatology product TWYNEO in mainland China, Taiwan, Hong Kong, Macau, and Israel.
Mithra Pharmaceuticals has entered into a license and supply agreement with Searchlight Pharma for the Canadian rights to Donesta.
Y.S.P. Industries has entered into an exclusive licensing agreement to develop and market TaiGen Biopharmaceuticals Holdings’ (TaiGen) new drug in Malaysia and Singapore.
Indian pharmaceutical firm Lupin has entered into an agreement to acquire five brands along with associated trademark rights from the units of Menarini -- A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings.
TheracosBio has announced the commercial availability of Brenzavvy (bexagliflozin) oral tablet for the treatment of adults with type 2 diabetes by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).
Astellas Pharma, through its indirect wholly owned subsidiary, Berry Merger Sub, has completed the acquisition of Iveric Bio.
Alvotech and Advanz Pharma have extended their strategic partnership for the supply and commercialisation of five biosimilars in Europe.
Nordic pharma company Navamedic ASA has offered $7.2m (SEK75m) to purchase all shares in Sweden-based pharmaceutical firm Sensidose AB.
Shenzhen Hepalink Pharmaceutical Group’s subsidiary OncoVent has entered into a licence and distribution agreement with Orient EuroPharma (OEP) for the immunotherapeutic drug candidate, oregovomab.
Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.